Stapokibart reduces blood eosinophil counts in patients with moderate-to-severe atopic dermatitis: a post-hoc analysis from phase II and phase III clinical trials.
J Dermatolog TreatJul 15, 2026 (epub)
Yan Zhao, Furen Zhang, Bin Yang et al.
✦ AI-curated · Sources linked
In 30 seconds
This post-hoc analysis from phase II and III trials evaluated the impact of stapokibart on blood eosinophil counts in patients with moderate-to-severe atopic dermatitis. The study found that stapokibart significantly reduced eosinophil counts compared to placebo, with high-dose treatment resulting in a reduction from 420 to 235 cells/μL and low-dose from 530 to 315 cells/μL at Week 16.
Key findings
- Stapokibart reduced blood eosinophil counts from 420 to 235 cells/μL in the high-dose group.
- In the low-dose group, eosinophil counts decreased from 530 to 315 cells/μL.
- EASI-75 response rates were higher in both eosinophil subgroups treated with stapokibart compared to placebo.
- The incidence of adverse events was similar across eosinophil subgroups, mostly mild or moderate.
Why it matters
Understanding the effects of stapokibart on eosinophil counts may inform treatment strategies for atopic dermatitis, particularly in patients with elevated eosinophil levels, potentially leading to improved management of the condition.